Racial/ethnic differences in the use of glucagon-like peptide-1 receptor agonists (GLP-1 agonists) for atherosclerotic cardiovascular disease (ASCVD) benefit in patients with type 2 diabetes
The use of GLP-1 agonists has been shown to improve various clinical outcomes. Further research may reveal methods to increase the use of these agents, which may reduce disease-related complications especially for the minority population.
Authors
- Amne Borghol (ORCID: https://orcid.org/0000-0002-0028-7174)
- Fahamina Ahmed (ORCID: https://orcid.org/0000-0001-7415-1117)
- Madison E Grady
- Susan Olet
- Sierra Meyers
- Lauren Rivera
Institutions
- Ochsner Health System (US)
- Xavier University of Louisiana (US)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2025-11-02
- DOI
- https://doi.org/10.1080/03007995.2025.2606551
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00